Original Source(s)
Related Content
FDA Expands Test for Gastric and Esophageal Cancers
According to Agilent Technologies, the expanded indication covers esophageal and gastric tumor types and applies to patients being considered for nivolumab or nivolumab and hyaluronidase-nvhy.
July 14, 2026
-
2 min